Skip to main content
. 2023;24(5):1797–1808. doi: 10.31557/APJCP.2023.24.5.1797

Table 1.

Clinicopathological Characteristics of the Studied Cases of HGGs and Its Correlation with PSMA Expression in TMV

Parameter PSMA expression in TMV Total number of studied cases (100%) P value
Negative staining Positive weak staining Positive moderate staining Positive strong staining
Number % Number % Number % Number %
Gender Male 9 25.70 14 40.00 11 31.40 1 2.90 35 **0.579
Female 7 20.60 12 35.30 11 32.40 4 11.80 34
Tumor site Cerebral Frontal 6 40.00 5 33.30 3 20.00 1 6.70 15 *0.266
Parietal 1 10.00 5 50.00 4 40.00 0 0.00 10 **0.598
temporal 3 21.40 3 21.40 6 42.90 2 14.30 14
Occipital 1 20.00 3 60.00 1 20.00 0 0.00 5
more than one lobe 1 7.70 7 53.80 3 23.10 2 15.40 13
Deeply seated 4 40.00 2 20.00 4 40.00 0 0.00 10
Cerebellar 0 0.00 1 50.00 1 50.00 0 0.00 2
Histological subtype Anaplastic astrocytoma 4 44.40 4 44.40 1 11.10 0 0.00 9 *0.022
Anaplastic oligodendroglioma 3 50.00 1 16.70 2 33.30 0 0.00 6 **0.163
Anaplastic ependymoma 0 0.00 1 50.00 1 50.00 0 0.00 2
classic GB 1 5.00 6 30.00 9 45.00 4 20.00 20
GB with oligodendroglial features 0 0.00 5 62.50 2 25.00 1 12.50 8
Recurrent GB 4 36.40 4 36.40 3 27.30 0 0.00 11
Gliosarcoma 4 30.80 5 38.50 4 30.80 0 0.00 13
Histological grade III 7 41.20 6 35.30 4 23.50 0 0.00 17 *0.054 **0.191
IV 9 17.30 20 38.50 18 34.60 5 9.60 52

*P-value according to positivity and negativity; ** P-value according to composite PSMA score; Chi square test